Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...
Enfortumab-vedotin plus pembrolizumab offers survival benefits but is less cost-effective than gemcitabine and cisplatin plus nivolumab, especially in Europe. Healthcare providers face challenges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results